Illumina Releases NovaSeq S4 Flow Cell and NovaSeq Xp Workflow
17 October 2017 - 12:00AM
Business Wire
Illumina, Inc. (NASDAQ:ILMN) today announced the availability of
the NovaSeq S4 flow cell, reagent kit and NovaSeq Xp workflow for
its NovaSeq™ 6000 System. Flow cell innovation is key to unlocking
the power and flexibility of the NovaSeq platform and the release
of this new flow cell and workflow extends the capabilities of the
platform to empower high intensity sequencing across a wide range
of sequencing methods.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171016005445/en/
The highly anticipated NovaSeq S4 flow
cell delivers up to 6TB of output in two days and is ideally suited
for high intensity sequencing applications. (Photo: Business
Wire)
The highly anticipated NovaSeq S4 flow cell delivers up to 6TB
of output in two days and is ideally suited for high intensity
sequencing applications. Users can now sequence up to 48 human
genomes or 384 exomes per run in less than 48 hours. This
innovation paves the way for large-population-scale initiatives at
the lowest price per sample, and enables labs to cost effectively
perform human whole genome sequencing.
“Our experience using the NovaSeq has exceeded our already high
expectations,” said David B. Goldstein, Ph.D., Director of the
Institute for Genomic Medicine at Columbia University. “We
anticipate that the S4 flow cell will enable us to further
accelerate large scale genomic studies to identify disease-causing
genes and the development of new treatment options. With the power
that the S4 delivers, we are planning to run our genomic studies at
a scale and cost that we would not have thought possible even a
year ago, with implications across our entire research and clinical
portfolio.”
The NovaSeq Xp workflow comprises the NovaSeq Xp flow cell
loading dock and reagents. The new appliance enables users to load
libraries directly into individual lanes of the flow cells, further
enhancing the flexibility of the system. Users can now partition
samples and projects by lane, enabling more efficient use of flow
cell whether mixing library types or implementing novel approaches
to sample indexing.
“We continue to deliver on our roadmap, bringing new, innovative
products to the genomics market. The S4 flow cell, coupled with our
recent launch of the IDT Unique Dual Indexes (UDIs) and our new
Nextera DNA Flex library preparation kit, represents a significant
milestone toward enabling large-scale, highly-powered whole genome
studies,” said Omead Ostadan, Executive Vice President, Products,
Operations and Strategy at Illumina.
“We expect the NovaSeq Series to continue to drive sequencing
towards higher intensity applications, higher depths of coverage,
and larger study sizes to properly power experiments. We believe
that the release of the S4 flow cell will accelerate this trend,”
said Joel Fellis, Ph.D., Director of Product Marketing at Illumina.
“The S4 is geared toward larger sample numbers and will enable
experiments such as 200x to 300x whole genome tumor profiling.”
The NovaSeq S4 flow cells are shipping immediately while the
NovaSeq Xp workflow components are expected to ship before the end
of the year. For more information, please visit
www.illumina.com/novaseq.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical, and applied
markets. Our products are used for applications in the life
sciences, oncology, reproductive health, agriculture, and other
emerging segments. To learn more,
visit www.illumina.com and follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve
risks and uncertainties. These forward-looking statements are based
on our expectations as of the date of this release and may differ
materially from actual future events or results. Among the
important factors that could cause actual results to differ
materially from those in any forward-looking statements are (i) our
ability to further develop and commercialize our instruments and
consumables, and to deploy new products such as the S1 and S4 Flow
Cells and NovaSeq Xp Workflow, services and applications, and
expand the markets for our technology platforms; (ii) our ability
to manufacture robust instrumentation and consumables; (iii) our
ability to successfully identify and integrate acquired
technologies, products or businesses; (iv) the future conduct and
growth of the business and the markets in which we operate; and (v)
challenges inherent in developing, manufacturing, and launching new
products and services, together with other factors detailed in our
filings with the Securities and Exchange Commission, including
our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We undertake no obligation, and do not
intend, to update these forward-looking statements, to review or
confirm analysts’ expectations, or to provide interim reports or
updates on the progress of the current quarter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171016005445/en/
Illumina, Inc.Jacquie RossInvestors:
858-882-2172IR@illumina.comorJen CarrollMedia:
858-882-6822PR@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024